Optimizing Novel Therapies and Surgery in Ear...

AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)

Up next

Navigating Therapeutic Advances in EGFR-Mutated NSCLC

Dr. Monty Pal and Dr. Vamsi Velcheti discuss the evolving treatment landscape in EGFR-mutated non-small cell lung cancer, including landmark trials like FLAURA2, novel drug therapies, and the growing importance of ctDNA and MRD testing. TRANSCRIPT Dr. Monty Pal: Hello, and welcom ... Show more

. 19min 24sec

Highlights From the 2026 ASCO GU Cancers Symposium

Dr. Monty Pal and Dr. Andrea Apolo discuss practice-changing studies and other novel approaches in bladder, kidney, and prostate cancers that were presented at the 2026 ASCO Genitourinary Cancers Symposium. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcas ... Show more

. 20min 9sec

Recommended Episodes

Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2024.1

ASCO Guidelines

Dr. Jyoti Patel discusses the latest update to the stage IV NSCLC with driver alterations living guideline, specifically for patients with EGFR or ROS1 alterations. She shares the latest recommendations based on recently published evidence, such as the FLAURA2, MARIPOSA-2, and TR ... Show more

. 12min 24sec

Systemic Therapy for SCLC: ASCO-OH (CCO) Guideline

ASCO Guidelines

Dr. Greg Kalemkerian joins us on the ASCO Guideline Podcast to discuss the newest ASCO – Ontario Health (Cancer Care Ontario) Guideline on systemic therapy for small-cell lung cancer (SCLC). He reviews the evidence-based recommendations from the panel, including guidance on syste ... Show more

. 27min 13sec

Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of CAP Guideline

ASCO Guidelines

Dr. Praveen Vikas, Dr. Tyler Johnson, and Dr. Russell Broaddus present the ASCO endorsement of the Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration With the Associa ... Show more

. 16min 31sec

Endocrine and Targeted Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer – Capivasertib-Fulvestrant: Rapid Guideline Update

ASCO Guidelines

Dr. Angela DeMichele, Dr. Lynn Henry, and Dr. Harold Burstein present the latest breast cancer rapid recommendation update impacting two ASCO guidelines. This update focuses on the new option, capivasertib plus fulvestrant, for patients with hormone receptor-positive, HER2-negati ... Show more

. 14min 9sec